C4 Therapeutics (CCCC) PT Lowered to $5 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CCCC Hot Sheet
Price: $3.21 -4.75%
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 3
Rating Summary:
12 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 12 | New: 3
Join SI Premium – FREE
Morgan Stanley analyst Terence Flynn lowered the price target on C4 Therapeutics (NASDAQ: CCCC) to $5.00 (from $6.00) while maintaining a Underweight rating.
You May Also Be Interested In
- C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Goldman Sachs Downgrades China Southern Airlines Co Ltd. (1055:HK) to Sell
- Checkpoint Software (CHKP) PT Raised to $135 at Wells Fargo
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
